CD4 and melanoma: To this end, we investigated the changes in the dLN, PBL, and tumor CD8+ T cell repertoires following anti-CD4 mAb treatment using unbiased high-throughput TCR sequencing (TCR-seq) in a B16F10 mouse subcutaneous melanoma model.